Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.

Haematologica - 1 Apr 2012

Kuriakose Emil, Vandris Katherine, Wang Y Lynn, Chow William, Jones Amy V, Christos Paul, Cross Nicholas C P, Silver Richard T

Abstract excerpt

BACKGROUND: Although reduction in the JAK2(V617F) allele burden (%V617F) has been suggested as a criterion for defining disease response to cytoreductive therapy in polycythemia vera, its value as a response monitor is unclear. The purpose of this study is to determine whether a reduction in %V617F in polycythemia vera is a prerequisite to achieving hematologic remission in response to cytoreductive therapy....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Alleles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Interferon-alpha

Share to Janus Kinase 2

Share to Polycythemia Vera

Share to Remission Induction

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 22102708
DOI: 10.3324/haematol.2011.053348
PMCID: PMC3347655

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.PMID 22102708Read ↗

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.Semantic proximity Read ↗

Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha.Semantic proximity Read ↗

Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia Vera.Semantic proximity Read ↗

[Interferon-alpha-2b induces molecular responses of patients with polycythemia vera and its post-polycythemic myelofibrosis].Semantic proximity Read ↗

Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemiaSemantic proximity Read ↗

Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera.Semantic proximity Read ↗

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.Semantic proximity Read ↗

Deciphering the complex clonal heterogeneity of polycythemia vera and the response to interferon alphaSemantic proximity Read ↗

Contemporary Use of Interferon Therapy in the Myeloproliferative Neoplasms.Semantic proximity Read ↗

Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia veraSemantic proximity Read ↗

Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.